AstraZeneca Reports Strong Q1 Growth Driven by Cancer Drug Sales

The pharmaceutical giant's earnings and revenue exceed expectations, bolstered by robust demand for oncology treatments.

AstraZeneca's first-quarter revenue surged to $12.68 billion, marking a 16.5% increase, with oncology treatments rising 23%.
Earnings per share reached $2.06, surpassing analysts' forecasts due to high sales of cancer drugs like Imfinzi and Tagrisso.
Shares of AstraZeneca climbed, approaching all-time highs, reflecting investor confidence in the company's financial performance.
The company's cardiovascular and metabolism drug segments also showed significant growth, contributing to the overall revenue boost.
AstraZeneca's recent acquisitions and positive trial results for lung cancer treatments underscore its robust pipeline and innovation in oncology.